Adial Pharmaceuticals Book Value Per Share Growth & History (ADIL)
Adial Pharmaceuticals's book value per share was $4.75 for fiscal 2025.
View full Adial Pharmaceuticals company overviewAdial Pharmaceuticals annual book value per share history
| Fiscal year | Period ended | Book value per share | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $4.75 | -$10.97 | −69.78% |
| 2024 | 2024-12-31 | $15.72 | -$45.66 | −74.39% |
| 2023 | 2023-12-31 | $61.37 | -$15.36 | −20.02% |
| 2022 | 2022-12-31 | $76.73 | -$27.93 | −26.69% |
| 2021 | 2021-12-31 | $104.66 | -$68.42 | −39.53% |
| 2020 | 2020-12-31 | $173.09 | -$257.34 | −59.79% |
| 2019 | 2019-12-31 | $430.43 | $25.94 | +6.41% |
| 2018 | 2018-12-31 | $404.49 | $595.27 | — |
| 2017 | 2017-12-31 | -$190.78 | — | — |
Adial Pharmaceuticals quarterly book value per share
| Fiscal quarter | Period ended | Book value per share | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | -$14.61 | -$21.10 | — |
| Q1 2026 | 2026-03-31 | $2.46 | -$5.53 | −69.19% |
| Q4 2025 | 2025-12-31 | $4.75 | -$10.97 | −69.78% |
| Q3 2025 | 2025-09-30 | $4.73 | -$18.24 | −79.42% |
| Q2 2025 | 2025-06-30 | $6.49 | -$18.41 | −73.94% |
| Q1 2025 | 2025-03-31 | $7.99 | — | — |
| Q4 2024 | 2024-12-31 | $15.72 | -$45.66 | −74.39% |
| Q3 2024 | 2024-09-30 | $22.96 | -$25.05 | −52.18% |
| Q2 2024 | 2024-06-30 | $24.90 | -$44.34 | −64.04% |
| Q4 2023 | 2023-12-31 | $61.37 | -$15.36 | −20.02% |
| Q3 2023 | 2023-09-30 | $48.02 | -$77.88 | −61.86% |
| Q2 2023 | 2023-06-30 | $69.24 | -$123.22 | −64.02% |
| Q1 2023 | 2023-03-31 | $31.56 | -$250.58 | −88.82% |
| Q4 2022 | 2022-12-31 | $76.73 | -$27.93 | −26.69% |
| Q3 2022 | 2022-09-30 | $125.89 | -$94.18 | −42.80% |
| Q2 2022 | 2022-06-30 | $192.46 | $28.48 | +17.37% |
| Q1 2022 | 2022-03-31 | $282.14 | $78.84 | +38.78% |
| Q4 2021 | 2021-12-31 | $104.66 | -$68.42 | −39.53% |
| Q3 2021 | 2021-09-30 | $220.07 | -$91.38 | −29.34% |
| Q2 2021 | 2021-06-30 | $163.98 | -$244.63 | −59.87% |
| Q1 2021 | 2021-03-31 | $203.30 | -$123.11 | −37.72% |
| Q4 2020 | 2020-12-31 | $173.09 | -$257.34 | −59.79% |
| Q3 2020 | 2020-09-30 | $311.45 | -$218.55 | −41.24% |
| Q2 2020 | 2020-06-30 | $408.61 | -$205.31 | −33.44% |
| Q1 2020 | 2020-03-31 | $326.41 | -$394.59 | −54.73% |
| Q4 2019 | 2019-12-31 | $430.43 | $25.94 | +6.41% |
| Q3 2019 | 2019-09-30 | $530.00 | $60.09 | +12.79% |
| Q2 2019 | 2019-06-30 | $613.92 | $840.99 | — |
| Q1 2019 | 2019-03-31 | $721.00 | — | — |
| Q4 2018 | 2018-12-31 | $404.49 | $595.27 | — |
| Q3 2018 | 2018-09-30 | $469.91 | — | — |
| Q2 2018 | 2018-06-30 | -$227.07 | — | — |
| Q4 2017 | 2017-12-31 | -$190.78 | — | — |
Adial Pharmaceuticals book value per share trends
Over the last five fiscal years, Adial Pharmaceuticals's book value per share decreased from $173.09 to $4.75, a change of -$168.34. The latest reported quarter, Q2 2026, shows -$14.61.
What book value per share means
Book value per share estimates the common shareholders’ accounting equity represented by each share. It can help compare a company’s balance-sheet value over time, although market value can differ substantially from book value.
How book value per share is calculated
TickerStat calculates book value per share as SEC-reported common shareholders’ equity divided by reported period-end common shares. Preferred equity is subtracted when separately reported, and basic weighted-average shares are used only when period-end shares are unavailable. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Adial Pharmaceuticals source filings ↗